Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

 

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Frontiers in Cancer Drug Development conference which is part of IBC's Drug Discovery and Development Week in Boston, MA. Dr. Bergstein's presentation, entitled "Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical and Clinical Update" is scheduled for 9:50AM on Wednesday August 5th at the World Trade Center/Seaport Hotel in Boston. Dr. Bergstein has also been invited to participate in a panel discussion following the presentations.
 

Cancer stem cell targeted therapeutics have emerged as the next frontier in the fight against cancer. As such, this field is significantly influencing current decision making with respect to oncology drug development. With this in mind, Dr. Bergstein's presentation will cover novel pre-clinical and clinical development paradigms, including human trial design, of drug candidates that target cancer stem cells. The talk will also feature Stemline's latest clinical data, as well as results from its pre-clinical pipeline and drug discovery platforms.
 

About Stemline Therapeutics, Inc.
 

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human clinical trial. Stemline is also developing a portfolio of biological and small molecule compounds directed at multiple high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called "StemScreen " which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at www.stemline.com.
 

Stemline Contact: Tom Cirrito, PhD, Director of Operations, Stemline
 

Therapeutics, Inc. Tel: 212-531-5976; Email: tcirrito@stemline.com
 

Source: Stemline Therapeutics, Inc.

CONTACT: Tom Cirrito, PhD, Director of Operations of Stemline
Therapeutics, Inc. +1-212-531-5976, tcirrito@stemline.com
 

Web Site: http://www.stemline.com

Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: July 2009

View comments

Hide
(web5)